Afatinib (BIBW2992)

Name: Afatinib (BIBW2992)
Brand: Selleck Chemicals
SKU: S1011
Rating: 5 (270 reviews)

For research use only.

Catalog No.S1011

270 publications

CAS No. 850140-72-6

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.

Selleck's Afatinib (BIBW2992) has been cited by 270 publications

Cancer Cell, 2021, S1535-6108(20)30609-7

PubMed: 33417832 ( click the link to review the publication )

Nat Cell Biol, 2021, 23(4):377-390

PubMed: 33795873 ( click the link to review the publication )

Nature, 2020, 584(7822):608-613

PubMed: 32848220 ( click the link to review the publication )

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Cancer Res, 2021, canres.2276.2020

PubMed: 33685992 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(2)E752

PubMed: 33451095 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Transl Oncol, 2021, 14(8):101110

PubMed: 33951601 ( click the link to review the publication )

Thorac Cancer, 2021, 10.1111/1759-7714.13931

PubMed: 33710795 ( click the link to review the publication )
Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

Lung Cancer, 2021, 154:84-91

PubMed: 33631449 ( click the link to review the publication )

Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w

PubMed: 33686255 ( click the link to review the publication )

PLoS Pathog, 2021, 17(2):e1009303

PubMed: 33529218 ( click the link to review the publication )

Toxicol Lett, 2021, S0378-4274(21)00043-6

PubMed: 33571620 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-00409-1

PubMed: 32958903 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.3555.2020

PubMed: 33355298 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01564-w

PubMed: 33288882 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Cancer Lett, 2020, 476:23-33

PubMed: 31958486 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):882

PubMed: 33082316 ( click the link to review the publication )

Cell Death Dis, 2020, 2;11(1):6

PubMed: 31919341 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 10(5):674-687

PubMed: 32213539 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )

J Virol, 2020, JVI.02001-20

PubMed: 33361428 ( click the link to review the publication )
Antimicrob Agents Chemother, 2020, 1;AAC.00341-20

PubMed: 32482675 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):129

PubMed: 32066410 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(3):605-619

PubMed: 32036454 ( click the link to review the publication )

Am J Transl Res, 2020, 15;12(3):847-856 eCollection 2020

PubMed: 32269717 ( click the link to review the publication )

Cancer Res Treat, 2020, 10.4143/crt.2020.585

PubMed: 33070556 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Korean J Parasitol, 2020, 58(3):249-255

PubMed: 32615738 ( click the link to review the publication )

Radiat Oncol, 2020, 15(1):58

PubMed: 32143669 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2020, 21(1):61

PubMed: 32795383 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Genome Biol, 2020, 21(1):181

PubMed: 32727536 ( click the link to review the publication )

J Cancer, 2020, 11(1):241-250

PubMed: 31892990 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.30172

PubMed: 33230821 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:376

PubMed: 32774169 ( click the link to review the publication )
Neurooncol Adv, 2020, Dec;2(1):vdaa020

PubMed: 32226941 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12982

PubMed: 32737414 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Oncoimmunology, 2019,

PubMed: 30713780 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )
Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )

Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9):e8746

PubMed: 30021798 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29880898 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )
Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )

J Am Chem Soc, 2018, 140(40):12785-12797

PubMed: 30256630 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(47):6581-6591

PubMed: 28783173 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )
Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28881811 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423495 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )
PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27207775 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27799141 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27680026 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )
J Cell Biol, 2015, 211(2):391-405

PubMed: 26483553 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

J Med Chem, 2015, 58(16):6589-606

PubMed: 26258521 ( click the link to review the publication )

Cancer Discov, 2015,

PubMed: 26243863 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: 25504185 ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Oncol Rep, 2015,

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25686822 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25537503 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )
Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )
J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	NFn5fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDhXXJKSzVyPUCuNFA2PzJizszN	NFfNTo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KASUMI-1	NIXIbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLqb4g2UUN3ME2wMlAxQTFzIN88US=>	MnnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCC2218	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnmZoVKSzVyPUCuNFA6QDdizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KARPAS-45	NGPLTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPOTWM2OD1yLkCxOlcyKM7:TR?=	NHH0c2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HSC-4	NFS4PHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMEG3OFgh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
CHL-1	NGrTSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLQT3VKSzVyPUCuNFE5OzlizszN	NGH1N\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KY821	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwMEKwOkDPxE1?	NES3dFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-N87	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfNTWM2OD1yLkCyO\|c{KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
DOK	M1nU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTuWWVKSzVyPUCuNFMyQTRizszN	M3PiVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
DSH1	M2\GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMEOzNVQh\|ryP	M1;HcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MDA-MB-175-VII	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3H6c2lEPTB;MD6wN\|QyPiEQvF2=	M3vhbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H2170	M4DOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYiwR3NIUUN3ME2wMlA{PzJ6IN88US=>	NFPDfW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
BT-474	NH:5bXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMES5PFYh\|ryP	NGT3dJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
EFO-27	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWT2VmI4UUN3ME2wMlA2OTh{IN88US=>	NITqbIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H720	MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3GxfmlEPTB;MD6wOVMzPSEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
PC-14	NYKzcoZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDTXVZ6UUN3ME2wMlA2PjZ6IN88US=>	M1vBVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EC-GI-10	NX73RYdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUP6[nVSUUN3ME2wMlA2QTF{IN88US=>	MkjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KYSE-450	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M371OWlEPTB;MD6wOVk4QCEQvF2=	M4nU[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
BPH-1	NITscplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfLXnlKSzVyPUCuNFU6QDhizszN	NEW3cXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H292	NGOzTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7sXY1KSzVyPUCuNFYxQSEQvF2=	NEHvb449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
H9	NHHTOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4T5VWlEPTB;MD6wO\|E{OiEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H526	NW\4SpB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1n5UWlEPTB;MD6wO\|gzOyEQvF2=	NGHnN5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1623	M4S3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjpdJJKSzVyPUCuNFgxOjVizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KYSE-140	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzpRo1EUUN3ME2wMlA5OzNizszN	Ml3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
Ca9-22	MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwMEizOVMh\|ryP	NWnOZVlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
AU565	M3XR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmSzTWM2OD1yLkC4OVA1KM7:TR?=	M1;FcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
ZR-75-30	NFjZXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIn2VG9KSzVyPUCuNFk2PDVizszN	MkL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H1770	NE\FW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLpTWM2OD1yLkGwNlgh\|ryP	NWGwTpBVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LB2241-RCC	NYnmNZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDDTWM2OD1yLkGwPFg1KM7:TR?=	NFjPVow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CAL-39	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYX1S3QyUUN3ME2wMlEyPzl{IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
UACC-893	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjXTFdKSzVyPUCuNVE5QDVizszN	NEHneWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LU-65	NVjqXZB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMUK2N\|Mh\|ryP	M2HPW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HN	NET1[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPhXZVKSzVyPUCuNVMxPzdizszN	NYX3WXF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
TI-73	MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rhUGlEPTB;MD6xOFcyPSEQvF2=	NV[wNpg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KU812	NWfBeml7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknrTWM2OD1yLkG1OFU3KM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW13	NUfLXFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4myNWlEPTB;MD6xOlIyPiEQvF2=	NWW5SIdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
BB30-HNC	NGfjSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PFc2lEPTB;MD6xOlU4PiEQvF2=	MljPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HSC-2	NEnIVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPuUo1KSzVyPUCuNVY5OzdizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
BV-173	M{XlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7wTWM2OD1yLkG3OVk3KM7:TR?=	Mon1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CAL-27	M{DDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMUe2N\|Yh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SBC-1	M4PCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrBOW9KSzVyPUCuNVg6PTlizszN	MkTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CAL-33	NWL2[VlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\yTWM2OD1yLkKwNVg1KM7:TR?=	NVKwfJk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H209	NHzLfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXDTWM2OD1yLkKwOFYh\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
COR-L105	M1rTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHFNINKSzVyPUCuNlExQDRizszN	NUnSN256RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HSC-3	Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMkGxPVgh\|ryP	NVH1cmczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H69	NWHR[Yg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMkG0OVEh\|ryP	NH\tZnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MOLT-13	NH3mVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMkO5O\|Uh\|ryP	NVjESJM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ML-2	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1f5VWlEPTB;MD6yOFgxOiEQvF2=	NUm4W5RNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
IGROV-1	M{ToeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDkUJJXUUN3ME2wMlI2QTV{IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
TK10	NHfjblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nrOGlEPTB;MD6yOlc{QCEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
EoL-1-cell	NHzjPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWj4S\|FyUUN3ME2wMlI3QDl{IN88US=>	M1PXeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HO-1-N-1	Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfnTWM2OD1yLkK3PFU{KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
BHY	NV3zdpN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXSTWM2OD1yLkK4OlU2KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LU-139	NEDzS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPL[2dMUUN3ME2wMlMxPTFizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
23132-87	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwM{G5NlMh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
ACHN	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\wV\|JiUUN3ME2wMlMyQTl2IN88US=>	NYXmdok4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
DoTc2-4510	M1LSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PO[2lEPTB;MD6zNlIyQSEQvF2=	MofIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BB65-RCC	NWXzV4FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjCSFdOUUN3ME2wMlM1PTl\|IN88US=>	NHzKUW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HLE	NWP1XWNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2K3bmlEPTB;MD6zOVA1PiEQvF2=	Mlv0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCC1419	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjaS3NQUUN3ME2wMlM3PDB6IN88US=>	NX3hOVRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
A388	NH3qfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwM{[4OVch\|ryP	NYrrT5ExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NUGC-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLETWM2OD1yLkO4N\|c{KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KYSE-180	NXfa[GFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3zWmdKSzVyPUCuN\|kxQDlizszN	NV\6SY5uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
TE-6	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TPR2lEPTB;MD60NFI1PiEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
A498	NXq3UHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwNEC2O\|Qh\|ryP	NYjzO4RWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1648	M1fjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{f2XWlEPTB;MD60OFE5OiEQvF2=	NVjVeVVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
DU-145	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwNES4N\|Mh\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
CW-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvPRo9KSzVyPUCuOFY6OTRizszN	NY\reGlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
A431	NH7R[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7TdHhKSzVyPUCuOFgzOzNizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SAS	MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\IZWlEPTB;MD60PFM6QCEQvF2=	M3L0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H2126	M1vwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwNUG5NlYh\|ryP	M3HlV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H358	NYXYV4V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX:1PYloUUN3ME2wMlU{OjFizszN	NGriSVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
FADU	M2\MTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTuTW1KSzVyPUCuOVQ1ODRizszN	NF7xZ5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
ACN	M3jLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X6TmlEPTB;MD61OVA6PCEQvF2=	MoX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCC70	NH3ofmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL2fHFSUUN3ME2wMlU4PjZzIN88US=>	NEDaZ449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1838	NWS1NpRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwNkCyPVkh\|ryP	MkHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CAL-54	NHHSfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LsRWlEPTB;MD62NVYzOSEQvF2=	NWTxWI12RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1975	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVWzPI9NUUN3ME2wMlYyPzJ6IN88US=>	NXrYVY5SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
COR-L88	NF7EV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIruVoRKSzVyPUCuOlQyOTNizszN	NX;zeow3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CTV-1	NGqzRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwNkSzPVIh\|ryP	M3nD[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EW-18	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXXfFBKSzVyPUCuOlg3QThizszN	NVSzcZJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HCC1806	M37mXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwNkm2OlYh\|ryP	M2fnTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HuP-T4	NV[1SY5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTp[mtPUUN3ME2wMlY6PzZizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MDA-MB-361	NELRclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPSUm02UUN3ME2wMlczPjZ{IN88US=>	MknnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H1573	NWHyd2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{C1OWlEPTB;MD63N\|Y{KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KU-19-19	M3Wwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDrTWM2OD1yLke3OFY1KM7:TR?=	M1PFdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
COLO-678	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwOEC4N\|Qh\|ryP	NULkO4E4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
C-33-A	NYDIPW9mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Ty[WlEPTB;MD64NVI6PyEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
Calu-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrpWYtKSzVyPUCuPFE1OzRizszN	NV7D[VRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
AGS	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwOEO2OFgh\|ryP	NEHqUFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SCC-25	NHrXWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXS3fXJFUUN3ME2wMlg1OTdzIN88US=>	MnXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
JVM-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XET2lEPTB;MD64PFI6QSEQvF2=	NWK4SZp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HCE-T	NUL4foxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwOEi0Nlgh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
ES4	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwOUe4N\|Yh\|ryP	M3:0Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EKVX	NFvYW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XYWWlEPTB;MT6wNVA3PCEQvF2=	MlfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
D-542MG	NGO5fYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHCSFJYUUN3ME2xMlAyODZ2IN88US=>	NIPOSWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW1116	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnmwTWM2OD1zLkCxNlg4KM7:TR?=	NWTX[FB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
5637	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjxV2tKSzVyPUGuNFE2OSEQvF2=	MlL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HT-1376	M4XQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vLVmlEPTB;MT6wNVUyOyEQvF2=	NUHTOYs2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NB69	M17MS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnWe2ZuUUN3ME2xMlAzQTR3IN88US=>	NEjCe2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
YKG-1	M4XqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTFwMEW0NVkh\|ryP	M1\LVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EW-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzmfo1WUUN3ME2xMlA4QDh\|IN88US=>	MlPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
GCIY	MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzqfVlKSzVyPUGuNFgyODRizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SK-MES-1	NEjLTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzReoVjUUN3ME2xMlEyPDh5IN88US=>	NWrUNFRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
PANC-08-13	M1nLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:5TWM2OD1zLkG2OFE3KM7:TR?=	MkHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SK-NEP-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrqTWM2OD1zLkG3OVE{KM7:TR?=	NHH6R\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW954	M3f4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3MTWM2OD1zLkKwNlE1KM7:TR?=	NVjKXHpzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-SNU-5	MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LiOGlEPTB;MT6yN\|kh\|ryP	M1uwWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW48	NWHic3FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3vTWM2OD1zLkK1OFMzKM7:TR?=	Mn;hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HT-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTFwMki3OVMh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
ETK-1	M{jPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfoTWM2OD1zLkO3OFU3KM7:TR?=	NF;rPIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SCC-15	NEfZNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTFwM{m0OVEh\|ryP	M1PXcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
DU-4475	NVrtVGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPhdGVKSzVyPUGuOFAyOjFizszN	M3;aWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NB5	NF3aR\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTFwNEGzNVch\|ryP	MkL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CFPAC-1	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTFwNEK0PVMh\|ryP	MoCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H630	NUfoUotST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnLdJZKSzVyPUGuOFU2QDJizszN	MnntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H82	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInLVG5KSzVyPUGuOVQxODZizszN	NX7BN5ZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ECC10	MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTFwNUWzOlkh\|ryP	NYH6Z3N2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
K5	NYOy[mV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M360NWlEPTB;MT61PFM2PyEQvF2=	Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
ME-180	NFv4dlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGG1XpBKSzVyPUGuOlExQTZizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KYSE-410	NVPiSohNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3NTWM2OD1zLk[1OlczKM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
G-401	NVj0SVc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33JTGlEPTB;MT62O\|QyOyEQvF2=	NVLySZZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
TGBC24TKB	NVi2fVZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:1TWM2OD1zLk[4NlMh\|ryP	M{fuUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
Detroit562	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHITWM2OD1zLkewNVUzKM7:TR?=	NFL0UJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
OE19	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTFwN{G1NVIh\|ryP	M2XpUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CAKI-1	NITOVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlO5TWM2OD1zLke4NlEyKM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
TE-12	NEnudYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTFwOEC0NVQh\|ryP	M3\qVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1666	M{PGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\ETWM2OD1zLkiwPVQ5KM7:TR?=	NWLGdWJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
TE-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzEcIMyUUN3ME2xMlgyPDd3IN88US=>	NWXGWGdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CAL-12T	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[2R2lEPTB;MT64PFk1PSEQvF2=	M4DuV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
TE-8	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjEfoRsUUN3ME2xMlkyOzd5IN88US=>	MmXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KYSE-270	MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnmyTWM2OD1{LkCyO\|MzKM7:TR?=	NH;mRXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
GMS-10	M3XtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvjXmdKSzVyPUKuNFM2OTdizszN	MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
A2780	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nESmlEPTB;Mj6wOlI6PCEQvF2=	NYq0RnFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
OMC-1	NF\DRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTJwMEixOlkh\|ryP	MkflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LoVo	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTEe3VsUUN3ME2yMlExPzl5IN88US=>	M2L2UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
PANC-03-27	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLGU5ZCUUN3ME2yMlE3PjNzIN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MDA-MB-157	NHv0OHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFe1TWNKSzVyPUKuNlE5OjhizszN	NVzsZpJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CaR-1	M4frVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPSfopKSzVyPUKuNlgzQDFizszN	NEjkXVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
769-P	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVqwO4RxUUN3ME2yMlI6ODN5IN88US=>	M{fQW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NB7	M2WyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\zfmlEPTB;Mj6yPVY4PiEQvF2=	NWfENYFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MKN7	NXW3fmN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTJwM{WzN\|Uh\|ryP	M4XWNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1048	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjnTWM2OD1{LkS5NVU5KM7:TR?=	MmX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
RCM-1	M2GxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vKU2lEPTB;Mj61Nlk{QCEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HT55	M3LrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[xcWlEPTB;Mj61O\|M5KM7:TR?=	NE\ISIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HCC1569	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlO4TWM2OD1{LkW4Nlk4KM7:TR?=	MmP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LXF-289	MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf6VZZKSzVyPUKuOlM2PjVizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
OVCAR-3	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jZNWlEPTB;Mj62O\|E3PyEQvF2=	NILzVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
TE-10	NEDWSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLKNW5KSzVyPUKuOlgxPzhizszN	NYnHUlNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SNU-C2B	NFu1OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7l[41KSzVyPUKuOlg3OTZizszN	NIW1O4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LB1047-RCC	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\BU2ZKSzVyPUKuO\|Q5QDhizszN	NWLzOGFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SN12C	NV;rWFMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7p[5hiUUN3ME2yMlkyQTZ2IN88US=>	MkWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
786-0	M{KwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjzc\|ZPUUN3ME2zMlA3PDB6IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HT-29	NWX1fY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTNwMEezNFkh\|ryP	Ml;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
RPMI-7951	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTNwMEe1PUDPxE1?	NY\hOI92RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NBsusSR	NVT4cFl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rvdGlEPTB;Mz6xPFI2PCEQvF2=	NEThO2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NKM-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1ywWWlEPTB;Mz6xPFc1PCEQvF2=	NVzqfVh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
Capan-2	NWLSU21PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXrO5lKSzVyPUOuOFY5PzVizszN	NV7GRoc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MKN1	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrxUZZSUUN3ME2zMlQ4OTB6IN88US=>	MmPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
OAW-42	NVvCXmJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnOSFN6UUN3ME2zMlUxODJ4IN88US=>	M3P3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SKG-IIIa	NYnKUppbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ztfWlEPTB;Mz61NlI{PyEQvF2=	NY\nVY5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
no-11	NEjDcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHR[3ZKSzVyPUOuOVM2PjRizszN	NIfkOGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NY	NEnMZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTiZ2hKSzVyPUOuOVM3PTVizszN	NUjNRYduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HEC-1	M4DIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTNwNUi5OUDPxE1?	M2LhR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H441	NEDmd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXoZYh6UUN3ME2zMlU6QDRzIN88US=>	NWS0RmtLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H2009	NI\CUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHLN\|JKSzVyPUOuOlEzOTZizszN	M3HvN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
T47D	NVT0[nFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWOxdWlpUUN3ME2zMlYzOjF5IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SNU-449	NHjaNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmixTWM2OD1\|Lk[1PFI3KM7:TR?=	M{Hzb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-SNU-1	NYHSVZNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTJ[4c5UUN3ME2zMlY6PzN3IN88US=>	M{LVXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
BT-20	NFXWWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTNwNkm3PVUh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LS-123	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PEZWlEPTB;Mz63OFI5PCEQvF2=	Mmr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
8305C	NE\1WZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTNwN{W5NVEh\|ryP	NWnjRnN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
OCUB-M	NXPud3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrFNHlDUUN3ME2zMlc3OTh5IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KOSC-2	M4fVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTNwOEO0OVEh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1693	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWW4WIY4UUN3ME2zMlg1OThzIN88US=>	M3\r[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
TE-9	MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\FTmlEPTB;Mz64OFM5OiEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MV-4-11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWS5SlNSUUN3ME2zMlg4QTl2IN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
GAMG	M{DXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTNwOUGzNVQh\|ryP	MlXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KNS-62	NUH1b4JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIH6R5JKSzVyPUOuPVQ4OzFizszN	NWnFSYtKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MC116	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\DTWM2OD1\|Lkm1OFg6KM7:TR?=	NIjjNmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
647-V	NW\OcmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWewWJRFUUN3ME2zMlk5PDV{IN88US=>	M1TrUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
U-87-MG	M33XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LRXWlEPTB;ND6xNFQ5OSEQvF2=	NGX5eJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
RPMI-8226	NGrxVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTRwMUG2N\|Eh\|ryP	M{nydFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW1417	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDMTWM2OD12LkGyNVQ4KM7:TR?=	NH\ZOmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LAMA-84	NXjzW29jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[2bpJKSzVyPUSuNVcxOiEQvF2=	NILvU3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LS-513	NXTnc2RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjKU4NKSzVyPUSuN\|EzOTdizszN	NGfPZYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KLE	NHXBcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTRwNEC4NVkh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HCT-116	M2TIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3Y[4VKSzVyPUSuOFExODdizszN	M3TBblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EPLC-272H	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3W1cGlEPTB;ND60NVU{OyEQvF2=	NUfQcmJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KS-1	M1vGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1S4XWlEPTB;ND61NFg5QSEQvF2=	NH;weGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HT-1197	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTRwNUK2Olkh\|ryP	NFXjSng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXq2Zo5QUUN3ME20MlU{Pjh4IN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
ES5	NY[zTVJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWe0SXg2UUN3ME20Mlg{PzJ\|IN88US=>	NXW3fo9FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CTB-1	MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPFR3NsUUN3ME20Mlg1QDhizszN	NVrhUWVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HL-60	NIe5dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX76WIFRUUN3ME20Mlg3PjFzIN88US=>	MnnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
VM-CUB-1	NY\xZVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrPTWM2OD12Lki2PFE6KM7:TR?=	Mli4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MEG-01	NVeyToY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4ntOGlEPTB;ND65PVQxOyEQvF2=	NUjIWFRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KYSE-520	NG\nWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTVwMkC4N\|kh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HuO-3N1	NG\OU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTVwMkSwOFMh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW620	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{D5VmlEPTB;NT6yOFk3PCEQvF2=	NYfTUYk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
U031	MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTVwMkW0NlQh\|ryP	M1GyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
TE-5	M3vhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfJO4ZKSzVyPUWuOFA5PSEQvF2=	M{nCZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H747	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1T3dGlEPTB;NT60NlQ4OiEQvF2=	NEGyOGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MG-63	M{nxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XEbGlEPTB;NT60PFc3OiEQvF2=	MoHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HC-1	NHW1SXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPFbGdYUUN3ME21MlUyQDN7IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HCC2998	NIjHSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjFSYtKSzVyPUWuOVI3OTVizszN	NX7uN5FORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NTERA-S-cl-D1	M3PyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;CN5cyUUN3ME21MlU1PTN5IN88US=>	M{njRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KINGS-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrUb21NUUN3ME21MlYxQTR2IN88US=>	M{L1WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
D-423MG	NITIe49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfNNolKSzVyPUWuOlE4ODVizszN	MlzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SW962	M2TKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvpRohKSzVyPUWuOlIxOzJizszN	M2\RdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
LOXIMVI	M2H2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHO[45KSzVyPUWuOlM5PzNizszN	NH:wcGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LS-411N	NEXve2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXiR5BKSzVyPUWuO\|k1PDFizszN	Mk[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H2291	NUnETIJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTVwOUi5OFMh\|ryP	NY[4PGc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
A549	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXPTWM2OD14LkGyOVU{KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LS-1034	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknGTWM2OD14LkKwO\|A3KM7:TR?=	M3PrRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NB14	MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTZwNEO4N\|Yh\|ryP	NEfkfXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1299	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYKwSZlzUUN3ME22MlY{OTdzIN88US=>	Mn7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BT-549	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTZwNk[4PFkh\|ryP	MkTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	NF\mNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DzeGlEPTB;Nj64Olkh\|ryP	NHTnSWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW756	M1T2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHxcoVKSzVyPU[uPVEyPzZizszN	NXeye3h6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
DJM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTZwOUKwNVIh\|ryP	MkfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
GP5d	NVPEZWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;BS\|VMUUN3ME22Mlk4Ozl2IN88US=>	M4q1S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MOLT-4	NVPsTFdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTdwMEKxN\|Uh\|ryP	NWXtRlE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H28	MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rkSWlEPTB;Nz6xOlQxPSEQvF2=	MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MN-60	MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTdwMkiwPFkh\|ryP	NFrOSo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
RMG-I	NH3rO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MormTWM2OD15LkO5Nlk3KM7:TR?=	NH\Qe\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
COLO-800	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTdwNEG0OFYh\|ryP	NWXjRpZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
DB	NIXQfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLkNIkxUUN3ME23MlYyODB3IN88US=>	NWnkPFNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
Ca-Ski	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnDTWM2OD15Lk[0NlU6KM7:TR?=	MmXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HEL	MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrGXI1KSzVyPUeuO\|EzODNizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NH-12	MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVexPINbUUN3ME23MlczQDB6IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LB373-MEL-D	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTdwN{[3O\|Eh\|ryP	NGDvS2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW900	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHvRotKSzVyPUeuPFIyOjFizszN	Mm\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
JVM-3	NVP1UXF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\MTWM2OD15Lki5OVk6KM7:TR?=	M1v0dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
OAW-28	M1TtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTdwOUS1O\|gh\|ryP	Mm\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KURAMOCHI	M1zN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXW4Um44UUN3ME23Mlk1QDFzIN88US=>	NFLzdpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
BE-13	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHjXphKSzVyPUeuPVgyOTJizszN	NHnTblY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
VMRC-RCZ	M3;lN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MluzTWM2OD16LkCxOlk4KM7:TR?=	NIPuUnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H727	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnDb2ZqUUN3ME24MlExPDJizszN	M2GyPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW1710	NYTtcJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHUW4RKSzVyPUiuNVg2OTVizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
D-502MG	MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\abmhHUUN3ME24MlI6Ojh{IN88US=>	MnPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H1993	NHfYUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjnfIZKSzVyPUiuN\|M3OzFizszN	NHW1fXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SCC-4	NVLIb5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTjUGdtUUN3ME24MlQ1ODV7IN88US=>	MkH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HAL-01	NXfKPVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3r4XGlEPTB;OD61NVkyKM7:TR?=	NXrH[HF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
GT3TKB	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjrb4VbUUN3ME24MlY4QTZ2IN88US=>	NIPRS3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SK-OV-3	M12zcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjFTWM2OD16LkexN\|I6KM7:TR?=	NXzxWohERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
COLO-829	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXzTWM2OD16LkiwPVc3KM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
OCI-AML2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vteWlEPTB;OD65OVQ5OSEQvF2=	M3nzTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
OS-RC-2	NVjGcXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHCZWRKSzVyPUmuNFIyQSEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
BFTC-909	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;GR2lEPTB;OT6wOlc6QSEQvF2=	Ml64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
EW-11	NULxXGJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\3TWM2OD17LkG3OlU{KM7:TR?=	NXzqe3pqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HCE-4	M4LXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXNeIx[UUN3ME25MlIyPTV6IN88US=>	Mn7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BALL-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4T0SWlEPTB;OT6yNVkxPyEQvF2=	NWfqbo9{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SF539	MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnyVnMyUUN3ME25MlI{PTZ{IN88US=>	NWDRUZNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CAMA-1	M3zhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknDTWM2OD17LkK4NVI5KM7:TR?=	M2fpWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
C32	M{\yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTlwM{OwOlQh\|ryP	MmnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H1703	NYGxfpk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HlNWlEPTB;OT6zOFM4PSEQvF2=	M1yzXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1650	NHPzU\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkH2TWM2OD17Lk[wPVQ3KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1563	NXq0b5l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorCTWM2OD17Lke2NFMyKM7:TR?=	NHu5dGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CAL-85-1	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\YcmlEPTB;OT64O\|M5OyEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
UM-UC-3	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z4ZWlEPTB;OT65OVA{KM7:TR?=	MkW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BxPC-3	NWLifXg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTFyLkC5O\|Ih\|ryP	NXHL[G9[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MHH-PREB-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojtTWM2OD1zMD6xPVk6KM7:TR?=	MonkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
DEL	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M331bGlEPTB;MUCuN\|k1PiEQvF2=	NFTnZ3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HuCCT1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jGdmlEPTB;MUCuOlA{OyEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
OVCAR-4	M3\0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Lr[mlEPTB;MUCuPFg{PSEQvF2=	M170NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CAL-72	NEPJfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PXPGlEPTB;MUCuPVM6OSEQvF2=	M{nRdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HCC1954	NVfWW5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELJUlNKSzVyPUGxMlA4PTRizszN	MoD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
EFO-21	NYe1fo5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[5SWlEPTB;MUGuNVA1PSEQvF2=	NHixbGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
FTC-133	Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFzLkG0NFch\|ryP	MkL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SK-MEL-24	M{DVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfITWM2OD1zMT6yN\|Y3KM7:TR?=	NF3GfGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
UACC-62	M3vaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVK1cYVNUUN3ME2xNU4zOzZ6IN88US=>	NEf1bog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H650	NHHJXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\rZZFQUUN3ME2xNU4zPDF6IN88US=>	M{HGZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
ALL-PO	NFPnN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWizW3ZGUUN3ME2xNU4zPTF{IN88US=>	M{i2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
T84	NGTKeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFSzbZRKSzVyPUGxMlM6ODdizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
IST-MEL1	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFzLkS1OVkh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW626	NYDu[4ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTFzLkW3OVUh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
RPMI-2650	NHKzcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\qOmlEPTB;MUGuOVg5PSEQvF2=	M2nHRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MC-IXC	NEjkN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi4eFB[UUN3ME2xNU43PzJ6IN88US=>	M2r0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HOP-62	NISw[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHve2V7UUN3ME2xNU43PzZ2IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NOS-1	NGDqN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3Le3VKSzVyPUGxMlcyODlizszN	Mn\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SW1573	NV;FWHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYixTJdLUUN3ME2xNU44Ojl3IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
WM-115	NInkWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTFzLke1PFgh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HuO9	NE[0bYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfETYFKSzVyPUGxMlg4PzRizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
YAPC	NEjGTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PO[mlEPTB;MUGuPVI2QSEQvF2=	NXT2WohHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MDA-MB-453	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjNTWM2OD1zMT65OVE2KM7:TR?=	MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H596	NGnqelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr0clBKSzVyPUGyMlA{PjlizszN	M{Gw[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
A172	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTF{LkC3PVgh\|ryP	M3TGW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
RS4-11	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1P2OWlEPTB;MUKuNVczPSEQvF2=	NXfuWoZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HCC1937	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{ToNWlEPTB;MUKuO\|U3PCEQvF2=	NYfBTJA3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SW837	NHm1ZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrPc4NKSzVyPUGyMlkxOjhizszN	NYO2R3lqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NMC-G1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jvdmlEPTB;MUKuPVI{PCEQvF2=	MlXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
PFSK-1	NFjZSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTF\|LkC2JO69VQ>?	MlG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
DBTRG-05MG	NH:zc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3XNHdKSzVyPUGzMlA3OzJizszN	NEKxSYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SK-UT-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[yTIxKSzVyPUGzMlExQDNizszN	NYfRd49xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
OVCAR-5	NYXvSWk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHnTnQyUUN3ME2xN{4yPTl\|IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
8505C	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPGXo9FUUN3ME2xN{4zODZ5IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	M3KwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4n6OmlEPTB;MUOuO\|E{PSEQvF2=	M2\ZXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
LK-2	Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPLOG1YUUN3ME2xN{44PjN7IN88US=>	M{fzXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
OE33	NHqwS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnqTWM2OD1zMz63PFYh\|ryP	MkS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	NWjsSmd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTF2LkCyNFIh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
EW-13	M{XlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3nbGJKSzVyPUG0MlA{PTJizszN	NHr2W\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1793	M2TpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\KcXlXUUN3ME2xOE4zODh5IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
BHT-101	NIrjS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoH0TWM2OD1zND6yOFEh\|ryP	NX;mcmNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RKO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTF2LkWwO\|Uh\|ryP	M2T2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NEC8	NGj1NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTF2LkW0O\|Ih\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
PANC-10-05	NUHlboo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTF2Lk[yOFch\|ryP	NYPrT3J7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H2030	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\WNZNKSzVyPUG0MlY1PDhizszN	NGnkXIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
C2BBe1	M37QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmW3TWM2OD1zND63OlQh\|ryP	NV3zTVhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
EM-2	M3e4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\hW5FnUUN3ME2xOE45PTd4IN88US=>	NWLDO\|dlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HCC1395	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnqcnNKSzVyPUG0Mlk{OzhizszN	Mn7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
A2058	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHJVVBKSzVyPUG1MlA1ODlizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW1463	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHtdZdUUUN3ME2xOU4xPDh3IN88US=>	NEjV[mE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
J82	NIfSWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTF3LkC1O{DPxE1?	NITwUYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CAL-120	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHFTWM2OD1zNT6xOFQ4KM7:TR?=	MnXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
COLO-824	NWmyS5dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTF3LkG1O\|kh\|ryP	M{P3OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
LNCaP-Clone-FGC	NYHwVm1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3[2V2lEPTB;MUWuOFI1QCEQvF2=	NFvBc489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CP66-MEL	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjuTWM2OD1zNT60Olg5KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
OC-314	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2myWmlEPTB;MUWuOFcyPCEQvF2=	NU\Fb5VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
OVCAR-8	M4rmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHpSGJtUUN3ME2xOU45QDZzIN88US=>	M2X2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MFE-280	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HEOWlEPTB;MU[uNFQ5QCEQvF2=	M4PwfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MHH-NB-11	NU\nWXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL0XWlKSzVyPUG2MlA5OzlizszN	MoC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SW1990	M3nXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTF4LkG3OVUh\|ryP	NUSw[pRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
U-266	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLQTWM2OD1zNj6yNlk6KM7:TR?=	MoXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MFM-223	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;oZ2lEPTB;MU[uN\|k3PSEQvF2=	MmDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
L-363	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7jTWM2OD1zNj60OVc4KM7:TR?=	M{\MVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MCF7	M{LENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTF4LkS3NlMh\|ryP	NFTGfZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SK-MEL-3	NVqzXlIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUmwVXk6UUN3ME2xOk41Pzh5IN88US=>	NVm5WG1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HH	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDYWG1KSzVyPUG2MlUyPjJizszN	NES5[YI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
no-10	M4Dncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HwTWlEPTB;MU[uOlM1OyEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HuP-T3	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTF4Lk[1O\|Yh\|ryP	NWrhfIhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
QIMR-WIL	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHs[YZCUUN3ME2xOk44OTB3IN88US=>	NXPre4lRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1092	NHTvcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTYZ2NCUUN3ME2xOk45OzF4IN88US=>	NYC2WGNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MZ2-MEL	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELRSoxKSzVyPUG2Mlg1ODNizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
ES3	M3;ITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrJb4lKSzVyPUG2MlkyOzRizszN	MkW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
COLO-684	Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLQeXJKSzVyPUG2Mlk1PzdizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H661	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfEbo9KSzVyPUG2Mlk3QTRizszN	MoLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CP50-MEL-B	M1vXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XqbmlEPTB;MUeuNFM1OyEQvF2=	NH3xToE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H2405	M2r3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MluwTWM2OD1zNz6xPVc1KM7:TR?=	M1;qfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
U-2-OS	M1n6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:3TWM2OD1zNz61N\|A4KM7:TR?=	MlzEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
RERF-LC-MS	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LNSmlEPTB;MUeuOVUxQCEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H2342	NVewWZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnnXGo3UUN3ME2xO{42PTdizszN	NH\NOYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
ES8	NVjWU3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fMZ2lEPTB;MUeuOlA5PyEQvF2=	MkLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MOLT-16	NXPRXoVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXl[5JKSzVyPUG3Mlg6OzRizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
RH-18	M1TZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\M[oFnUUN3ME2xPE4xODN3IN88US=>	M{KyeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
D-283MED	NGLHTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3npOGlEPTB;MUiuNFA5QCEQvF2=	NWCzfXZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RCC10RGB	Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXJTWM2OD1zOD6wOVU6KM7:TR?=	NYDqT\|RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1437	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\1bmhKSzVyPUG4MlE3PDFizszN	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SW982	NEC1fo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDHe4oyUUN3ME2xPE4zPjdzIN88US=>	NVzmOY5ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
IST-MES1	M2PIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPBTINKSzVyPUG4MlQ1OjhizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
A704	NWnL[JNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXXZXhuUUN3ME2xPE41PzV\|IN88US=>	NUPBdVhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ESS-1	MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLiW2RKSzVyPUG4MlUzODVizszN	NHzXZWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SCH	M1zySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\vS4dKSzVyPUG4MlY1PTZizszN	M2\yWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
COLO-320-HSR	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF6Lke0OkDPxE1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
Mo-T	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTF6LkiyNFQh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
Saos-2	NWPIWVVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rEdGlEPTB;MUmuNVE3OiEQvF2=	M1H2XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW684	M3zMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HFRWlEPTB;MUmuNVMzPiEQvF2=	MoXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KMOE-2	M4ewc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTF7LkKyOFIh\|ryP	M1fzZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MMAC-SF	NV7ze5VyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;aTWM2OD1zOT6yOlA4KM7:TR?=	NHq5TZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
JAR	NVixXFhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLZTWM2OD1zOT6yPVkh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SK-MEL-28	M{X2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTF7LkOzOlMh\|ryP	NVHYXIRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KNS-81-FD	NIfi[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTF7LkW0Olgh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
ES7	NHzT[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXhTWM2OD1zOT62NlkzKM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
AsPC-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2ezbWlEPTB;MUmuOlQ4OSEQvF2=	NEf2PHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1155	M{PXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTF7LkeyN\|gh\|ryP	NFjDfWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KYSE-510	NVHESY86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;BPWhsUUN3ME2xPU45PzR6IN88US=>	M33Uc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
ES1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXVdZRqUUN3ME2xPU46OjF\|IN88US=>	NUe5VIkxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
PC-3	MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjoWZNKSzVyPUG5Mlk3ODRizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
GCT	NYjhfHpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TrfGlEPTB;MkCuN\|AzPiEQvF2=	Mke4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KARPAS-299	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTJyLkO0NlIh\|ryP	M3vHclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
DOHH-2	NVj2VJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPRSWhKSzVyPUKwMlU1PjNizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
COLO-741	NWe0Sms{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4P6PWlEPTB;MkCuOlYh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1395	M320Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUCwU\|JSUUN3ME2yNE43Pjl5IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HCC1187	NWfvUFVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkD2TWM2OD1{MD62O\|M1KM7:TR?=	NFS4THk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
Becker	NWfnOXdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk[zTWM2OD1{MD63NlAyKM7:TR?=	NWPkOmlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LU-134-A	M{LEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTJzLkGwNlYh\|ryP	MkjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MKN45	NW\hRoVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37hdmlEPTB;MkGuNVU2OSEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LC-2-ad	M{nxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nWSmlEPTB;MkGuNlczQSEQvF2=	Mnf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
EW-24	M4Lo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX[w[5l[UUN3ME2yNU4{QTR3IN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SK-N-AS	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mny5TWM2OD1{MT64Nlc3KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H2052	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1frRWlEPTB;MkGuPFk3OyEQvF2=	NUe2bGQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
A4-Fuk	M3HtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3[3OmlEPTB;MkKuNVQyQSEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NB10	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\acnVkUUN3ME2yNk4zOzdzIN88US=>	NHXyb3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CHP-212	M1K4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrC[\|FKSzVyPUKyMlMzOjJizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KM12	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXzTGtCUUN3ME2yNk4{PTZizszN	M{HVOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
JEG-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmWzTWM2OD1{Mj6zO\|gh\|ryP	NXjXO25uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LN-405	NU\SWotwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTJ{LkW5NVMh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HCT-15	NHTRdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzHTWM2OD1{Mj63OFQyKM7:TR?=	NYHPSJJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MLMA	NWfOO2lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXURoZKSzVyPUKyMlc1PyEQvF2=	NV7Xdo0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
GI-1	MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTJ{Lke2OVgh\|ryP	M4H3TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
RT-112	NIXMdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3NTWM2OD1{Mj64OlE3KM7:TR?=	NHTZVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MPP-89	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;DTWM2OD1{Mj64OlYyKM7:TR?=	MmjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
A3-KAW	NY\0eXloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLtU3JFUUN3ME2yN{4yODB\|IN88US=>	M2HUVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KALS-1	M3LKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4riZ2lEPTB;MkOuNVQyPCEQvF2=	NGnO[449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SF126	M{jNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7LNpVQUUN3ME2yN{43QTJ2IN88US=>	NHXmO\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SiHa	NIXBdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3JT3BKSzVyPUKzMlk{OjdizszN	NV;EfndlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MDA-MB-415	M3:zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTJ\|Lkm0PVkh\|ryP	MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
Daoy	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Pwc2lEPTB;MkSuNVI3KM7:TR?=	NIW5SZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
COR-L23	NYf5O3F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq0XHlpUUN3ME2yOE4yPzZ5IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KG-1	NGf6ZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTJ2LkG5Nlgh\|ryP	M4jqNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
L-428	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HW[mlEPTB;MkSuOVc6OSEQvF2=	Mme0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H520	MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjy[IJKSzVyPUK0Mlg5PjFizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
COLO-792	M3rrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHGbWlKSzVyPUK1MlI4OzJizszN	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NB12	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTJ3LkK5OFch\|ryP	NYXkOFc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
GAK	NXn4RXJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlOwTWM2OD1{NT6yPVY{KM7:TR?=	MnTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SW780	NWns[oRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHrPVdKSzVyPUK1MlMzPjRizszN	NUnue404RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
GB-1	NYjr[2wyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3P4VmlEPTB;MkWuOFA3QSEQvF2=	NEnXNVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	M2TxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjxfGM1UUN3ME2yOU41Pzh3IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1651	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoSxTWM2OD1{NT61PVch\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KE-37	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nCdmlEPTB;MkWuO\|MyPSEQvF2=	M1\NclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CCRF-CEM	NEDJZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJ3Lkm2O{DPxE1?	M1iwS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SF295	NYjQWHpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHroUo9KSzVyPUK2MlA1OjVizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
G-361	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTGTWM2OD1{Nj6xNFI4KM7:TR?=	NX[wNHo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HOP-92	NXzuWHVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHP2bnRKSzVyPUK2MlEzOjZizszN	M4jnUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
UMC-11	NGfVNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\aemlEPTB;Mk[uOFUyPCEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
IST-SL1	M3nwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUW0NphoUUN3ME2yOk43PTlzIN88US=>	MnPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
TE-11	M3e3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HXb2lEPTB;Mk[uO\|c2OiEQvF2=	Mn7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H1304	NWjtRYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTJ4LkmxNFgh\|ryP	NGDadY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SJSA-1	NEDQe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\5TIRKSzVyPUK3MlAyPzZizszN	NXvHVGRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
BCPAP	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXRVIZKSzVyPUK3MlE{PyEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HTC-C3	NHnPdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYCwSWw5UUN3ME2yO{4zPTZzIN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
EW-16	M1m0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJ5LkK5OFch\|ryP	NYTvRZJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HT-144	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTJ5LkSwN\|Ih\|ryP	M3;POFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MHH-ES-1	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;WTWM2OD1{Nz60OFQ4KM7:TR?=	MlHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
T98G	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPsR4FmUUN3ME2yO{42QDR4IN88US=>	NVH4[nRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RPMI-8866	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPlVFhCUUN3ME2yO{44PTZ{IN88US=>	NXe4WWVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
BEN	NXvyR413T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTJ5Lki1NVch\|ryP	NF\WNVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MDA-MB-231	NYjmcnAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzEOnlKSzVyPUK4MlI4QTVizszN	NIfVWFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HuH-7	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTJ6LkSwNlgh\|ryP	M3nwZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SK-N-FI	NEHxWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTJ6LkSzN{DPxE1?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
AN3-CA	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jFXmlEPTB;MkiuOFM6PSEQvF2=	NVnmT2tERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
EGI-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PvSGlEPTB;MkiuOVkzQCEQvF2=	NVfDWoRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
697	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJ6Lk[zN\|Eh\|ryP	NGGwZoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
TCCSUP	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTJ6Lk[0NVgh\|ryP	Mn60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
GR-ST	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NES3d5ZKSzVyPUK4MlY3QTZizszN	NYi3TIR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SK-N-DZ	NY\ON\|U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrZb5Z7UUN3ME2yPE43QDh3IN88US=>	NEXiO489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MIA-PaCa-2	NEHUS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfPTWM2OD1{OD63PVU6KM7:TR?=	Mn7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
IGR-1	MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHWTWM2OD1{OD64PFc1KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
BFTC-905	M13OTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PweWlEPTB;MkmuNlcxPSEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1581	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTJ7LkOxOFUh\|ryP	NH:yRVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
RD	NVfPdGhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzmTWM2OD1{OT61NlM{KM7:TR?=	Ml\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SF268	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PiemlEPTB;MkmuOVk{OSEQvF2=	NFHJUYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SHP-77	NXPE[\|B2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33OPWlEPTB;MkmuOlE5OiEQvF2=	Mkj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
D-566MG	NWHI[VJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLEWWI5UUN3ME2yPU46Ozl\|IN88US=>	MlTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
TGBC1TKB	M3r0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEX1[WZKSzVyPUOwMlEzOzhizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MEL-HO	M4fod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjkcVJKSzVyPUOwMlE1OjNizszN	MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SJRH30	MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{WxfGlEPTB;M{CuNlExQCEQvF2=	M2q2UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
D-336MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3VTWM2OD1\|MD6yPFkzKM7:TR?=	NG\OU\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
C3A	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXJemxKSzVyPUOwMlI6OjdizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
Calu-6	MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDhTWM2OD1\|MD6yPVY{KM7:TR?=	Mmi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MZ1-PC	NIXzSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvqdnBKSzVyPUOwMlM6OyEQvF2=	MkH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KYSE-70	MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnseJlCUUN3ME2zNE42OTF2IN88US=>	MlnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CAPAN-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTNyLkWxPFEh\|ryP	NH;4Zpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
DK-MG	MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTNyLkW0OVYh\|ryP	M1TZTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SK-HEP-1	M4Oxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLVc2pJUUN3ME2zNE43OzJ4IN88US=>	NGrTVFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MS-1	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LlWGlEPTB;M{CuPFg5QSEQvF2=	MoHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
GI-ME-N	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HtPWlEPTB;M{GuNFU4OSEQvF2=	Mn;2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H510A	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jiZWlEPTB;M{GuOFAxPiEQvF2=	NHLafWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NB17	M1XibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTNzLkWxPFUh\|ryP	NG\jSpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
639-V	NGq5SZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTNzLkWyOFMh\|ryP	NX73[pRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CAL-51	NVPiV25QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTNzLkW2Olch\|ryP	M{KwOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HGC-27	NVXwSlVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITyeXZKSzVyPUOxMlU5PzNizszN	M4q4UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
GOTO	NIPNfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjFNlFKSzVyPUOxMlg2ODZizszN	NX\V[XNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ChaGo-K-1	MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr0TWM2OD1\|Mj6wNFch\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
RO82-W-1	NXXSVYxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTN{LkG2NFQh\|ryP	NUmzSWJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SH-4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnIfHJKSzVyPUOyMlE5PThizszN	M37LcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
A204	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zkUWlEPTB;M{KuOVA3QSEQvF2=	MnXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
DMS-273	NU\NRoZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDMT2d1UUN3ME2zNk42OzJ{IN88US=>	M{TLO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KGN	M4K5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTN{Lk[zN{DPxE1?	NEDUSnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SK-MEL-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NES4S25KSzVyPUOyMlY2OjdizszN	NIewV5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H2228	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj6ZYpKSzVyPUOyMlY3ODJizszN	NFv6R4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MKN28	NGjHd\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTN{Lke4N\|gh\|ryP	NX:4enJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
H-EMC-SS	NUPyb3NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTN{Lkm2O\|gh\|ryP	NUWxc4xPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ATN-1	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jZ[mlEPTB;M{OuNVQyPiEQvF2=	MmS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
D-263MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrNPGhKSzVyPUOzMlg{PzhizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LU-135	NED1VYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7yT5RKSzVyPUOzMlg5OjlizszN	MonNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
C8166	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnQUGpKSzVyPUOzMlg5PTRizszN	NIS4Vo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
T-24	NYS3OGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XHdmlEPTB;M{SuNFIxPSEQvF2=	MoPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
Mewo	Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjPfnNXUUN3ME2zOE4yOzR7IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
22RV1	NVvFcnM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTN2LkG3OVQh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KM-H2	M1TCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LFWGlEPTB;M{SuNVc4QSEQvF2=	MmC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H2122	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moe3TWM2OD1\|ND6zOFcyKM7:TR?=	NUexW3JbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ABC-1	M3jVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\HTWM2OD1\|ND6zOlk{KM7:TR?=	M3PQTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1355	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;GUI5YUUN3ME2zOE4{QDh7IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NOMO-1	NUXEdYlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXkelJKSzVyPUO0MlU4ODNizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MZ7-mel	NFzMfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DGcGlEPTB;M{SuOlQ5PyEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H810	M2XKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULRXFNuUUN3ME2zOE44Ojd6IN88US=>	Mn\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
D-392MG	M2LKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnS0TWM2OD1\|NT6wOVY2KM7:TR?=	NYe2XmJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LB771-HNC	NHfqOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTN3LkG2OVgh\|ryP	NWjBOGNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
COLO-679	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2WzVmlEPTB;M{WuN\|g5KM7:TR?=	NGPqWXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SK-PN-DW	NVn0fJBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTN3LkSzOlkh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	NELtWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjVeHhKSzVyPUO1MlQ3PDlizszN	NEnTbnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KNS-42	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXn2OYRlUUN3ME2zOU42QDJ4IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
RVH-421	NWTnVXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7QTWM2OD1\|NT63OlQ2KM7:TR?=	NE\ZU4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
P30-OHK	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37EeWlEPTB;M{WuPFc2OiEQvF2=	NH;VdWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
G-402	NULX[3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjiVFRqUUN3ME2zOU46QDZ5IN88US=>	NVvud2NbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
S-117	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTN4LkOwNFgh\|ryP	NH7qfG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
RXF393	MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjZTWM2OD1\|Nj6zO\|g2KM7:TR?=	M1P6TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
LCLC-103H	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\TVJpKSzVyPUO2Mlc5ODNizszN	NFvvT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
U-118-MG	NVPlfGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1j4XWlEPTB;M{[uPFg1PyEQvF2=	M3;RPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
8-MG-BA	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn2[W1kUUN3ME2zOk46PDh\|IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MFH-ino	M{TIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTN5LkOzO\|Eh\|ryP	NX3sR\|lQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H23	M3GwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLqTWM2OD1\|Nz60NVk3KM7:TR?=	MnrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H446	NH3NZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XSVGlEPTB;M{euOFg3OiEQvF2=	Mmr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LU-99A	NUTBXosxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\Vc2JKSzVyPUO3MlU4OzFizszN	M3LRO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KP-N-YN	M1rhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorLTWM2OD1\|Nz62NVk2KM7:TR?=	NF3me5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SCC-9	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrIZ3VoUUN3ME2zO{44QDN6IN88US=>	NE\6ZYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
EFM-19	NEfo[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{W2VmlEPTB;M{euO\|k3PyEQvF2=	NVO3UYtDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
A427	NFjzSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTN5LkmxNFch\|ryP	NGrjb\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LB831-BLC	M2P5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\nTWM2OD1\|OD62NFM6KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HOS	NF[xZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrRUpFkUUN3ME2zPU43Ojd\|IN88US=>	NGW3c4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LAN-6	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIX0RVFKSzVyPUSwMlAyOTJizszN	M1jzXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
U251	NHq2fohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XrZmlEPTB;NECuOFA2PCEQvF2=	MoXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SNU-387	NUTuN2NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fqOWlEPTB;NECuOFU2OyEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
DMS-79	MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3H6XGlEPTB;NECuOVg5QSEQvF2=	NVPmUYpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SK-LU-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTqTWM2OD12MD62OVY5KM7:TR?=	NXfLN45WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HT	NIPEZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLkfYtKSzVyPUSwMlY3OzlizszN	NIXveGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KP-N-YS	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH4[mh7UUN3ME20NE43PzZ6IN88US=>	MoLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
DMS-114	NYnPPIVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXe5S\|luUUN3ME20NE45Ozd2IN88US=>	NG\UVoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HUTU-80	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnkXJBMUUN3ME20NU4xPTZ7IN88US=>	M333XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
ONS-76	NYL3Z41JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:w[HFWUUN3ME20NU41PzB7IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
A673	NVTLNppNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXPe2FoUUN3ME20NU42OTV5IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HPAF-II	M2P2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfGTWM2OD12MT62O\|A6KM7:TR?=	M2PnN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
UACC-257	NEXQdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEK2PJJKSzVyPUSxMlc{PjlizszN	M4fXZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EW-22	MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M371VGlEPTB;NEGuPFY6PyEQvF2=	NX;yb4R7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1755	NIC5U4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPCUHJtUUN3ME20NU45PzJ3IN88US=>	NYTh[2hYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KYSE-150	M1T0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP5cVhKSzVyPUSyMlE4QDJizszN	MnrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CGTH-W-1	M2CyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DFe2lEPTB;NEKuOFk2PSEQvF2=	NVG3NZh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NB13	M3y4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLQdohTUUN3ME20Nk43OjF5IN88US=>	NGr3SlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW872	NH3le2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGe0[W1KSzVyPUSyMlY{OzFizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KP-4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTR{Lki4N\|Ih\|ryP	NEjsbmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HCC38	M{mz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHuZXhbUUN3ME20Nk46PjF6IN88US=>	NEnaPJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
BB49-HNC	NETvNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojNTWM2OD12Mz6yN\|U3KM7:TR?=	M2fkd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CAL-62	NEH6TXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M331WWlEPTB;NEOuOFAzQCEQvF2=	NITsW3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H2029	M3fsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWP4OFY{UUN3ME20N{42PThzIN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
M14	NV[zOW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTR2LkGzN\|Ih\|ryP	M4fvUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
COLO-680N	MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVz6bZdWUUN3ME20OE4{OzlizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
Hs-578-T	NGjPO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3e5bWlEPTB;NEWuNFI6PCEQvF2=	NGTuPZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MSTO-211H	NHvr[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4e1ZWlEPTB;NEWuPVQ5OiEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
EW-1	NXL3bVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTR3Lkm2PFkh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW948	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXUTWM2OD12Nj60OFYzKM7:TR?=	NH\MRYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H460	NHyyTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTR4LkWyN{DPxE1?	NWfwR3I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CAS-1	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrCTWM2OD12Nj63O\|AyKM7:TR?=	MmrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
TGBC11TKB	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGr5RYJKSzVyPUS3MlE4PzdizszN	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTR6Lke4OkDPxE1?	NH63S3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H226	NFP2d5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDYcZdNUUN3ME20PU44Pzh3IN88US=>	NEjGN3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
PA-1	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTR7LkizN\|Uh\|ryP	NXTGOnRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LB2518-MEL	NFP6[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3e0WGlEPTB;NEmuPFczOyEQvF2=	NYjRWFZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
A101D	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nrN2lEPTB;NEmuPVQzPSEQvF2=	M3XkeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H2087	NWTnfWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVflVHV5UUN3ME20PU46Pjh{IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	850140-72-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04497584	Not yet recruiting	Drug: Afatinib + Prednisone	Advanced Squamous Non Small Cell Lung Cancer	University of Texas Southwestern Medical Center	March 1 2021	Phase 2
NCT04413201	Recruiting	Drug: Afatinib\|Drug: Osimertinib	Non-squamous NSCLC	Michael Hopp\|Boehringer Ingelheim\|Johannes Gutenberg University Mainz	September 11 2020	Phase 4
NCT04206787	Recruiting	Drug: Afatinib	Non-squamous Non-Small Cell Lung Cancer	Boehringer Ingelheim	May 20 2020	--
NCT04158947	Recruiting	Drug: Afatinib\|Drug: T-DM1	HER2-positive Breast Cancer\|Brain Metastases	xuexin he\|Second Affiliated Hospital School of Medicine Zhejiang University	May 10 2020	Phase 2
NCT03711422	Unknown status	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)